In a move designed to address the persistent issue of medication non-adherence driven by high costs, the healthcare software giant Epic has announced the upcoming launch of "Prescription Marketplace." This new digital tool is engineered to provide clinicians and health systems with a comprehensive view of medication pricing, including both insurance-backed co-pays and direct cash prices, at the point of care. By integrating real-time pricing data directly into the electronic health record (EHR) workflow, Epic aims to empower physicians and patients to make informed financial decisions before a prescription is even transmitted to the pharmacy.
The initiative comes at a critical juncture for the American healthcare system. According to data from the Kaiser Family Foundation (KFF), more than 40% of American adults currently report that they do not take their medications as prescribed due to concerns regarding cost. This phenomenon, often referred to as "cost-related non-adherence," leads to worsened clinical outcomes, increased emergency room visits, and billions of dollars in avoidable healthcare expenditures annually. The Prescription Marketplace seeks to mitigate these issues by removing the "sticker shock" that patients frequently experience at the pharmacy counter, which often results in prescriptions being left unfilled.
The Mechanics of the Prescription Marketplace
The Prescription Marketplace is designed as an evolution of Epic’s existing clinical tools. When a clinician prepares to prescribe a medication, the software will display a side-by-side comparison of costs. This includes the patient’s out-of-pocket cost through their specific insurance plan—integrated via real-time benefit check (RTBC) technology—and the "cash price" available at various pharmacies.
The inclusion of cash prices is a significant shift in the industry. Historically, insurance-negotiated rates were assumed to be the lowest cost for the patient. However, with the rise of high-deductible health plans and the emergence of direct-to-consumer pharmacy models, the cash price is increasingly lower than the insurance co-pay for many common generic medications. By surfacing these discrepancies within the EHR, Epic allows doctors to guide patients toward the most affordable acquisition channel, whether that is through their traditional pharmacy benefit manager (PBM) or a cash-based provider.
Strategic Partnerships: Amazon Pharmacy and Cost Plus Drugs
To build the foundation of this marketplace, Epic is collaborating with two major disruptors in the pharmaceutical space: Amazon Pharmacy and the Mark Cuban Cost Plus Drug Company. These organizations have built their business models on price transparency and the reduction of traditional middleman markups.
Mark Cuban, co-founder of Mark Cuban Cost Plus Drugs, emphasized the necessity of this transparency at the point of care. He noted that if a patient’s insurance mandates a $500 cost for a drug that is available for $100 via a cash-based model, the patient must be made aware of that option before they leave the doctor’s office. The partnership with Epic ensures that Cost Plus Drugs’ transparent pricing model—which is based on the actual cost of the drug plus a fixed 15% margin—is visible to the prescriber in real-time.
Similarly, Amazon Pharmacy brings its logistical scale and consumer-centric pricing to the platform. By integrating these providers, Epic is creating a competitive environment where pharmacies must compete on price and convenience, ultimately benefiting the patient.
Addressing the Crisis of Medication Non-Adherence
The primary driver behind this technological development is the measurable impact of non-adherence on public health. Joel Jones, Epic’s Vice President of Clinicals and Therapeutics and Patient Safety Officer, highlighted that when a patient cannot afford a medication, the treatment is effectively useless.
"Cost-driven non-adherence to prescriptions is a clear, measurable problem," Jones stated. He noted that by embedding the lowest-cost options, including cash prices, into the clinician’s workflow, Epic is attempting to dismantle one of the most significant barriers to effective treatment.
Furthermore, the Prescription Marketplace aims to solve a data gap for clinicians. Currently, if a patient pays for a medication with cash, that transaction does not always sync back to their clinical record or insurance claims data. This creates a "blind spot" for doctors. When a patient returns for a follow-up and their condition hasn’t improved, the doctor may assume the drug was ineffective, when in reality, the patient may have never filled the script or was taking it sparingly to save money. The new marketplace seeks to bridge this gap, providing clearer insights into whether a clinical failure is due to the drug’s efficacy or the patient’s inability to access it.
Chronology and Technological Evolution
The launch of the Prescription Marketplace is not an isolated event but the next step in a multi-year strategy by Epic to enhance pharmacy transparency.
- Pre-2020: Most clinicians had no visibility into what a patient would pay for a drug until the patient reached the pharmacy.
- 2020–2024: Epic expanded its "Real-Time Prescription Benefit" (RTPB) feature. This tool connects with payers and PBMs to show clinicians the exact co-pay for a patient based on their specific plan and deductible status.
- 2025 (Projected Milestone): Epic reports that its Real-Time Prescription Benefit feature has already saved patients more than $250 million in 2025 alone by suggesting generic alternatives and identifying lower-cost therapeutic equivalents.
- Summer 2027: The scheduled release of the "Prescription Marketplace." This update will expand the RTPB to include cash-price comparisons and direct integration with pharmacies like Amazon and Cost Plus Drugs.
This timeline reflects the technical complexity of integrating disparate data sources, including PBM formularies, real-time pharmacy inventory, and fluctuating cash-price lists, into a singular, low-latency interface that does not disrupt the physician’s workflow.
Industry Reaction and Critical Analysis
While the announcement has been largely met with optimism, industry experts suggest that transparency is only the first step in a much larger battle against healthcare costs.
Jeff Park, President of Waltz Health, a digital prescription drug company, praised the initiative as "directionally correct" and a "great step forward." However, he raised concerns regarding the burden placed on clinicians. Park argued that while giving doctors more information is beneficial, the technology should ideally automate the decision-making process.
"We shouldn’t expect [clinicians] to sort through prices, their benefit rules, what’s covered, what alternatives are available, which pharmacy selections, which manufacturer programs, all that during a doctor visit," Park said. He suggested that the next evolution of this technology should involve AI-driven systems that perform this analysis in the background and present the "clinically appropriate, lowest-cost choice" without requiring manual comparison by the physician.
Other analysts point out that while Epic’s marketplace addresses the "out-of-pocket" cost for the patient, it does not necessarily address the underlying "list price" of medications set by manufacturers. However, by surfacing cash prices, Epic may exert downward pressure on PBMs to lower co-pays for generic drugs to remain competitive with cash-based alternatives.
Broader Implications for the Healthcare Ecosystem
The introduction of the Prescription Marketplace by Epic—a company that holds the medical records of more than 250 million people—has the potential to shift the power dynamics within the pharmaceutical supply chain.
1. Impact on Pharmacy Benefit Managers (PBMs)
For decades, PBMs have operated with significant opacity, often utilizing "spread pricing" and complex rebate structures. By making cash prices visible at the point of care, Epic is effectively introducing a "market-clearing" mechanism. If patients and doctors consistently choose cash prices over PBM-negotiated co-pays, PBMs may be forced to simplify their pricing structures and reduce the "clawbacks" and fees that often drive up the cost of generic drugs.
2. Patient Empowerment via MyChart
A critical component of this rollout will be the integration with MyChart, Epic’s patient portal. This will allow patients to view their prescription options on their own devices. If a doctor prescribes a medication, the patient can see the different price points at various local and mail-order pharmacies. This transparency encourages patients to become active consumers of healthcare, rather than passive recipients of a complex system.
3. Clinical Outcomes and Population Health
From a population health perspective, the long-term goal is a reduction in chronic disease complications. Conditions such as hypertension, diabetes, and high cholesterol are often managed via low-cost generics. When patients adhere to these regimens, the risk of high-cost events like strokes or heart attacks decreases. By ensuring these medications are affordable from day one, health systems can significantly improve their performance in value-based care contracts.
4. The Future of the Doctor-Patient Relationship
The "cost conversation" has historically been one of the most awkward aspects of a medical consultation. Many doctors feel ill-equipped to discuss drug prices because they lack accurate data. The Prescription Marketplace provides a factual basis for these discussions, allowing the doctor and patient to collaborate on a treatment plan that is both clinically sound and financially sustainable.
Conclusion
The release of Epic’s Prescription Marketplace in 2027 represents a significant milestone in the digital transformation of healthcare. By leveraging partnerships with innovative pharmacy providers and integrating complex pricing data into the heart of the clinical workflow, Epic is addressing the root cause of medication non-adherence: affordability.
While the tool will not solve the entirety of the American drug-pricing crisis, it provides a vital mechanism for transparency. As the healthcare industry continues to move toward value-based care, the ability to ensure that patients can actually afford the treatments they are prescribed will become a cornerstone of clinical success. The challenge for Epic and its partners over the next two years will be to ensure that this wealth of information is presented in a way that simplifies, rather than complicates, the delivery of care. Regardless of the hurdles, the move marks a definitive shift toward a more transparent and patient-centric pharmaceutical marketplace.
